Table 1.
KRAS OR (Association with mutation occurrence and each covariate) | KRAS HR (Association with survival within each subgroup) | |
---|---|---|
| ||
Stage 1 | ||
Stage I | Referent | 0.85 (0.44, 1.63) |
Stage II | 1.05 (0.56, 1.91) | 1.43 (0.70, 2.90) |
Stage III | 0.77 (0.46, 1.27) | 0.94 (0.58, 1.53) |
Stage IV | 0.81 (0.54, 1.23) | 1.44 (1.10, 1.90) |
Histology 2 | ||
Squamous cell | Referent | 0.86 (0.30, 2.46) |
Adenocarcinoma | 9.67 (3.89, 31.83) | 1.39 (1.11, 1.75) |
Other | 7.51 (2.59, 27.05) | 0.87 (0.48, 1.57) |
| ||
Institution 1 | ||
MSK | Referent | 1.72 (1.13, 2.61) |
DFCI | 1.38 (0.73, 2.60) | 1.63 (0.97, 2.73) |
VICC | 1.43 (0.64, 3.12) | 1.62 (0.88, 2.98) |
Sex 3 | ||
Male | Referent | 1.71 (1.09, 2.67) |
Female | 1.55 (0.86, 2.86) | 1.55 (1.11, 2.16) |
Age (years) 4 | 1.04 (1.01, 1.07) | |
Race 1 | ||
White | Referent | 1.51 (1.11, 2.06) |
Asian | 0.12 (0.01, 0.53) | 0.96 (0.14, 6.73) |
Black | 1.09 (0.28, 3.64) | 25.91 (1.55, 433.56) |
Other | 0.51 (0.02, 3.69) | 2.57 (0.04, 157.78) |
Smoking History 1 | ||
Never | Referent | 0.98 (0.30, 3.19) |
Ever | 11.70 (4.52, 39.47) | 1.43 (1.07, 1.91) |
Age at diagnosis and sex included in the model.
Age at diagnosis, sex, and stage at diagnosis included in the model.
Age at diagnosis included in the model.
Sex included in the model.